Barth, Teresa and Zeman, Florian and Helbig, Horst and Gamulescu, Maria-Andreea (2018) Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia. INTERNATIONAL OPHTHALMOLOGY, 38 (1). pp. 191-198. ISSN 0165-5701, 1573-2630
Full text not available from this repository. (Request a copy)Abstract
Purpose To assess the long-term outcome of patients with subretinal neovascular membrane (SRNVM) secondary to type 2 idiopathic juxtafoveolar telangiectasia (IJT) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. Methods A total of 14 eyes of 12 patients treated with intravitreal anti-VEGF for SRNVM related to type 2 IJT were retrospectively assessed. Results Nine men and 3 women with a mean age of 66 years (SD 12, range 47-87 years) were diagnosed with IJT-related SRNVM. On average, 6.8 injections (SD 5.5, range 3-18) were given per eye. Ten eyes were treated with ranibizumab, 3 eyes with bevacizumab and 1 eye received both substances. The median follow-up after the last injection was 31 months (IQR: 18, 48). In 6 eyes, BCVA improved by 1-4 lines (mean Delta +2.0 lines), 1 eye remained stable and 7 eyes showed decline of vision by 1-5 lines (mean Delta -2.1 lines). The baseline central foveal thickness was significantly reduced from a mean of 323 (SD 87) to 266 mu m (SD 71 lm) at the last follow-up visit (p = 0.001). Conclusions SRNVM development is a severe complication of type 2 IJT. Since the establishment of intravitreal anti-VEGF treatment laser coagulation and PDT have lost significance. Intravitreal anti-VEGF therapy seems to be safe and effective for the treatment of IJT-related SRNVM. Frequently multiple intravitreal injections are necessary for stabilisation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-FACTOR THERAPY; MACULAR TELANGIECTASIA; PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN; RETINAL TELANGIECTASIS; RANIBIZUMAB; 2A; MEMBRANE; Subretinal neovascular membrane; Idiopathic juxtafoveolar telangiectasia; Intravitreal antiangiogenic therapy; Anti-VEGF (vascular endothelial growth factor) |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Augenheilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2020 06:46 |
| Last Modified: | 19 Mar 2020 06:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15093 |
Actions (login required)
 |
View Item |
